248 related articles for article (PubMed ID: 33328343)
1. Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular Cancer.
Pinato DJ; Fessas P; Cortellini A; Rimassa L
Clin Cancer Res; 2021 Feb; 27(4):908-910. PubMed ID: 33328343
[TBL] [Abstract][Full Text] [Related]
2. Camrelizumab: an investigational agent for hepatocellular carcinoma.
Xu B; Sun HC
Expert Opin Investig Drugs; 2022 Apr; 31(4):337-346. PubMed ID: 34937475
[TBL] [Abstract][Full Text] [Related]
3. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
[TBL] [Abstract][Full Text] [Related]
4. Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma.
Kuo HY; Chiang NJ; Chuang CH; Chen CY; Wu IC; Chang TT; Tsai HM; Lin YJ
Oncol Res Treat; 2020; 43(5):211-220. PubMed ID: 32101878
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
6. Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma.
Yang Y; Wang C; Sun H; Jiang Z; Zhang Y; Pan Z
Cancer Gene Ther; 2021 Feb; 28(1-2):89-97. PubMed ID: 32533100
[TBL] [Abstract][Full Text] [Related]
7. Camrelizumab combined with apatinib in the treatment of patients with hepatocellular carcinoma: a real-world assessment.
Chen D; Chen X; Xu L; Wang Y; Zhu L; Kang M
Neoplasma; 2023 Aug; 70(4):580-587. PubMed ID: 37789782
[TBL] [Abstract][Full Text] [Related]
8. Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma.
Guo L; Li H; Fan T; Ma Y; Wang L
Life Sci; 2021 Aug; 279():119359. PubMed ID: 33753114
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
[TBL] [Abstract][Full Text] [Related]
10. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
Cheng AL; Hsu C; Chan SL; Choo SP; Kudo M
J Hepatol; 2020 Feb; 72(2):307-319. PubMed ID: 31954494
[TBL] [Abstract][Full Text] [Related]
11. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.
Xu J; Zhang Y; Jia R; Yue C; Chang L; Liu R; Zhang G; Zhao C; Zhang Y; Chen C; Wang Y; Yi X; Hu Z; Zou J; Wang Q
Clin Cancer Res; 2019 Jan; 25(2):515-523. PubMed ID: 30348638
[TBL] [Abstract][Full Text] [Related]
12. Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy.
Jiang Y; Tu X; Zhang X; Liao H; Han S; Jiang W; Zheng Y; Zhao P; Tong Z; Fu Q; Qi Q; Shen J; Zhong L; Pan Y; Fang W
Support Care Cancer; 2020 Nov; 28(11):5569-5579. PubMed ID: 32361828
[TBL] [Abstract][Full Text] [Related]
13. Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma.
Yao X; Wang L; Gao J
Biosci Trends; 2019; 13(3):282-283. PubMed ID: 31327798
[TBL] [Abstract][Full Text] [Related]
14. Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?
Uson Junior PLS; Nagalo BM; Ahn DH; Bekaii-Saab T; Borad MJ
Semin Liver Dis; 2021 May; 41(2):136-141. PubMed ID: 33957697
[TBL] [Abstract][Full Text] [Related]
15. [Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: a multicenter retrospective study].
Yuan GS; He WM; Hu XY; Li Q; Zang MY; Cheng X; Huang W; Ruan J; Wang JJ; Hou JL; Chen JZ
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):326-331. PubMed ID: 33979958
[No Abstract] [Full Text] [Related]
16. Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib.
Zhang Z; Zhou Y; Hu K; Li Z; Wang Z; Huang Y
Dig Liver Dis; 2019 Oct; 51(10):1488-1490. PubMed ID: 31401020
[No Abstract] [Full Text] [Related]
17. Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience.
Mahn R; Vogt A; Kupczyk P; Sadeghlar F; van Beekum K; Hüneburg R; Meyer C; Toma M; Ahmadzadehfar H; Essler M; Matthaei H; Lingohr P; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
Scand J Gastroenterol; 2020 Sep; 55(9):1057-1062. PubMed ID: 32692941
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention.
Tian M; Shi Y; Liu W; Fan J
Sci China Life Sci; 2019 Sep; 62(9):1138-1143. PubMed ID: 31119560
[TBL] [Abstract][Full Text] [Related]
19. Hepatectomy combined with apatinib and camrelizumab for CNLC stage IIIb hepatocellular carcinoma: a phase II trial protocol.
Huang JT; Zhong JH; Zhang J; Gong WF; Ma L; Li LQ; Xiang BD
BMJ Open; 2023 Sep; 13(9):e067730. PubMed ID: 37770273
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular Carcinoma Growth Retardation and PD-1 Blockade Therapy Potentiation with Synthetic High-density Lipoprotein.
Wang J; Meng J; Ran W; Lee RJ; Teng L; Zhang P; Li Y
Nano Lett; 2019 Aug; 19(8):5266-5276. PubMed ID: 31361965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
